The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CTONG1103: Final overall survival analysis of the randomized phase 2 trial of erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non–small cell lung cancer.
 
Yi-Long Wu
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; Lilly; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)
 
Wenzhao Zhong
Honoraria - AstraZeneca; Roche
 
Ke-Neng Chen
No Relationships to Disclose
 
Chun Chen
No Relationships to Disclose
 
Fan Yang
Consulting or Advisory Role - AstraZeneca; Roche
 
Xue-Ning Yang
No Relationships to Disclose
 
Chundong Gu
No Relationships to Disclose
 
Weimin Mao
No Relationships to Disclose
 
Qun Wang
No Relationships to Disclose
 
Gui-Bin Qiao
No Relationships to Disclose
 
Ying Cheng
No Relationships to Disclose
 
Lin Xu
No Relationships to Disclose
 
Changli Wang
No Relationships to Disclose
 
Mingwei Chen
No Relationships to Disclose
 
Hong-Hong Yan
No Relationships to Disclose
 
Ri-qiang Liao
No Relationships to Disclose
 
Xuchao Zhang
No Relationships to Disclose
 
Jinji Yang
No Relationships to Disclose
 
Si-yang Liu
No Relationships to Disclose
 
Qing Zhou
Honoraria - AstraZeneca; Roche